BDTX vs. FENC, GLUE, MGX, STRO, CHRS, ADVM, IVVD, SOPH, XFOR, and AVXL
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Fennec Pharmaceuticals (FENC), Monte Rosa Therapeutics (GLUE), Metagenomi (MGX), Sutro Biopharma (STRO), Coherus BioSciences (CHRS), Adverum Biotechnologies (ADVM), Invivyd (IVVD), SOPHiA GENETICS (SOPH), X4 Pharmaceuticals (XFOR), and Anavex Life Sciences (AVXL). These companies are all part of the "biological products, except diagnostic" industry.
Black Diamond Therapeutics (NASDAQ:BDTX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 9.1% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 11.3% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Fennec Pharmaceuticals has higher revenue and earnings than Black Diamond Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fennec Pharmaceuticals had 7 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 9 mentions for Fennec Pharmaceuticals and 2 mentions for Black Diamond Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.34 beat Black Diamond Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Fennec Pharmaceuticals received 152 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. Likewise, 65.29% of users gave Fennec Pharmaceuticals an outperform vote while only 63.33% of users gave Black Diamond Therapeutics an outperform vote.
Black Diamond Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Fennec Pharmaceuticals' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.
Black Diamond Therapeutics presently has a consensus target price of $12.25, suggesting a potential upside of 145.00%. Fennec Pharmaceuticals has a consensus target price of $17.33, suggesting a potential upside of 87.19%. Given Black Diamond Therapeutics' higher probable upside, research analysts clearly believe Black Diamond Therapeutics is more favorable than Fennec Pharmaceuticals.
Black Diamond Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.
Summary
Fennec Pharmaceuticals beats Black Diamond Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
